Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY25 results · Apr–Jun 2024
Solara Active Pharma Sciences reported revenue from operations of ₹363.49 crore (up 3.2% from Q1 FY24) and net loss of ₹13.46 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 363.49 | 352.31 | +3.2% | 299.43 | +21.4% |
| Other income | 0.56 | 2.04 | −72.5% | 1.70 | −67.1% |
| Total income | 364.05 | 354.35 | +2.7% | 301.13 | +20.9% |
| Profit before tax | (13.46) | (29.36) | Loss narrowed | (166.66) | Loss narrowed |
| Net profit for the period | (13.46) | (19.11) | Loss narrowed | (255.45) | Loss narrowed |
| Attributable to shareholders of the company | (13.47) | (19.55) | Loss narrowed | (255.34) | Loss narrowed |
| EPS, basic (₹) | (3.50) | (5.43) | not comparable | (70.93) | not comparable |
| Net margin (%) | -3.7 | -5.4 | -85.3 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 363.49 | 352.31 | +3.2% | 299.43 | +21.4% |
| Other income | 1.38 | 2.07 | −33.3% | 1.63 | −15.3% |
| Total income | 364.87 | 354.38 | +3.0% | 301.06 | +21.2% |
| Profit before tax | (12.32) | (30.13) | Loss narrowed | (167.62) | Loss narrowed |
| Net profit for the period | (12.32) | (19.88) | Loss narrowed | (256.41) | Loss narrowed |
| EPS, basic (₹) | (3.20) | (5.52) | not comparable | (71.23) | not comparable |
| Net margin (%) | -3.4 | -5.6 | -85.6 |
Consolidated
- Filed with BSE
- 30 Aug 2024, 15:02 IST
- Board meeting
- 22 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Aug 2024, 15:02 IST
- Board meeting
- 22 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE